Core Insights - SciSparc Ltd. has announced the launch of an innovative initiative to advance 3D protein modeling using quantum computing technology, aiming to transform drug discovery with unprecedented accuracy in predicting protein structures and interactions [1][3] Company Overview - SciSparc Ltd. is a specialty clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders, with a portfolio that includes cannabinoid pharmaceuticals [4] Initiative Details - The new initiative will leverage quantum computing to simulate protein dynamics and interactions with ligands, which is expected to enhance the accuracy of drug discovery processes [3][6] - A dedicated research team will be formed to integrate quantum computing algorithms into 3D protein modeling, with initial efforts focusing on refining these algorithms for applications in neurological and rare diseases [3][6] - The company plans to establish a wholly owned Israeli subsidiary to operate this initiative [3] Importance of Protein Structure - Understanding a protein's 3D structure is critical for drug design and treatment of diseases, as proteins are dynamic and their functions depend on their unique shapes [2]

Core Viewpoint - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Premarket Gainers - AGM Group Holdings Inc. (AGMH) increased by 185% to $6.36 [3] - AlphaVest Acquisition Corp (ATMV) rose by 77% to $26.80 [3] - Brera Holdings PLC (BREA) saw a 20% increase to $30.00 [3] - Asset Entities Inc. (ASST) gained 18% to $4.54 [3] - 22nd Century Group, Inc. (XXII) also increased by 18% to $2.08 [3] - Millennium Group International Holdings Limited (MGIH) rose by 16% to $2.84 [3] - Robo.ai Inc. (AIIO) increased by 11% to $2.17 [3] - Butterfly Network, Inc. (BFLY) saw a 10% rise to $2.10 [3] - GrafTech International Ltd. (EAF) increased by 9% to $13.91 [3] - Cardlytics, Inc. (CDLX) rose by 8% to $2.99 [3] Premarket Losers - ECD Automotive Design, Inc. (ECDA) decreased by 14% to $3.70 [4] - Champions Oncology, Inc. (CSBR) fell by 8% to $6.11 [4] - Beam Global (BEEM) saw an 8% decline to $2.79 [4] - Fathom Holdings Inc. (FTHM) decreased by 8% to $2.19 [4] - Ventyx Biosciences, Inc. (VTYX) fell by 7% to $2.20 [4] - SciSparc Ltd. (SPRC) decreased by 6% to $4.35 [4] - Lightwave Logic, Inc. (LWLG) fell by 6% to $3.45 [4] - Jasper Therapeutics, Inc. (JSPR) decreased by 6% to $2.43 [4] - StableX Technologies, Inc. (SBLX) fell by 5% to $5.67 [4] - Galecto, Inc. (GLTO) decreased by 5% to $2.70 [4]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - 89bio, Inc. (ETNB) increased by 83% to $14.84 [3] - Aptevo Therapeutics Inc. (APVO) rose by 75% to $2.47 [3] - Psyence Biomedical Ltd. (PBM) saw a 29% increase to $4.82 [3] - Beam Global (BEEM) gained 27% reaching $3.23 [3] - MicroAlgo Inc. (MLGO) was up 14% at $13.06 [3] - Akero Therapeutics, Inc. (AKRO) increased by 12% to $47.50 [3] - Hyperion DeFi, Inc. (HYPD) rose by 11% to $13.69 [3] - Sonnet BioTherapeutics Holdings, Inc. (SONN) increased by 11% to $7.85 [3] - FuelCell Energy, Inc. (FCEL) was up 9% at $8.34 [3] - Robo.ai Inc. (AIIO) gained 6% to $2.05 [3] Premarket Losers - Presidio Property Trust, Inc. (SQFT) decreased by 14% to $7.58 [4] - Aeluma, Inc. (ALMU) fell by 10% to $15.18 [4] - FGI Industries Ltd. (FGI) dropped 10% to $7.65 [4] - Lazydays Holdings, Inc. (GORV) was down 9% at $2.26 [4] - StableX Technologies, Inc. (SBLX) decreased by 8% to $5.40 [4] - Artelo Biosciences, Inc. (ARTL) fell by 8% to $4.48 [4] - SciSparc Ltd. (SPRC) decreased by 8% to $4.10 [4] - Cracker Barrel Old Country Store, Inc. (CBRL) was down 7% at $45.75 [4] - Columbus Circle Capital Corp I (BRR) fell by 7% to $9.42 [4] - Visionary Holdings Inc. (GV) decreased by 7% to $2.58 [4]

Core Viewpoint - SciSparc Ltd. experienced a significant stock price increase of 89.13% to $3.48 in after-hours trading following a court-granted stay in merger proceedings with AutoMax Motors Ltd. [1] Group 1: Merger Proceedings - The Jerusalem District Court has granted AutoMax's request to delay merger proceedings until September 30 due to concerns about completing the merger and meeting closing conditions [2] - A merger agreement was signed between SciSparc and AutoMax on April 10, 2024, which has been revised due to operational difficulties at AutoMax [3] Group 2: Stock Performance - In 2025, SciSparc's stock saw a significant decline of 75.66%, with a high of $22.47 on January 6 and a low of $1.80 by Monday, with trading volume dropping to 123,000 shares [4] - The market capitalization of SciSparc is $2.98 million, with the stock trading between $1.75 and $37.59 over the past year, and it remains down 71.87% despite the recent surge [5] - During the regular trading session on Tuesday, the stock experienced a 2.22% increase [5]

Group 1 - SciSparc Ltd. announced the approval of a merger with AutoMax Motors Ltd., enhancing its operations into the automotive sector [1][2] - The merger will result in SciSparc acquiring 100% of AutoMax's share capital through a reverse merger, with SciSparc shareholders expected to hold approximately 50.01% of the combined company's share capital [2][3] - The merger aligns with SciSparc's long-term strategy to diversify its portfolio and capitalize on the expanding electric vehicle market in Israel [3] Group 2 - SciSparc has provided financial support to AutoMax, including a $4.25 million bridge loan in 2024 and an additional $2 million loan in February 2025 [3] - The closing of the merger is subject to customary closing conditions, including approval from the Israeli court [3] - SciSparc is a specialty clinical-stage pharmaceutical company focused on cannabinoid pharmaceuticals, with ongoing drug development programs targeting various disorders [4]

Core Viewpoint - SciSparc Ltd. has announced the approval of a strategic merger with AutoMax Motors Ltd., aiming to enhance shareholder value by diversifying into the automotive sector, particularly focusing on the electric vehicle market in Israel [2][3]. Group 1: Merger Details - The merger will involve SciSparc acquiring 100% of AutoMax's share capital through a reverse merger, with AutoMax continuing as a wholly-owned subsidiary [2]. - Following the merger, SciSparc shareholders are expected to hold approximately 50.01% of the combined company's share capital [2]. - The merger is part of a definitive agreement entered into on April 11, 2024, and marks a significant step in expanding SciSparc's operations [2][3]. Group 2: Financial Support and Strategy - SciSparc has previously supported AutoMax's growth with financial assistance, including a $4.25 million bridge loan in 2024 and an additional $2 million loan in February 2025 [3]. - The merger aligns with SciSparc's long-term strategy to diversify its portfolio and capitalize on the expanding electric vehicle market in Israel [3]. Group 3: Closing Conditions - The closing of the merger is subject to customary closing conditions, including shareholder approvals from both companies and Israeli court approval [4]. - Special meetings for AutoMax's shareholders to vote on the merger approval are scheduled for August 28, 2025 [4]. Group 4: Company Overview - SciSparc Ltd. is a specialty clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders, with ongoing drug development programs based on cannabinoid pharmaceuticals [5]. - The company also has a controlling interest in a subsidiary that sells hemp seed oil-based products on the Amazon.com Marketplace [5].

Core Viewpoint - Clearmind Medicine Inc. has announced the publication of an international patent application for a combination therapy aimed at treating metabolic syndrome and obesity, in collaboration with SciSparc Ltd. [1][2] Group 1: Patent and Collaboration - The patent application covers a combination therapy of Clearmind's proprietary 5-methoxy-2-aminoindane (MEAI) and SciSparc's Palmitoylethanolamide (PEA) [2] - This collaboration has resulted in the filing of 13 patent families across multiple jurisdictions, including the United States, Europe, and China [4] - The focus of the collaboration is on developing therapies that combine neuroplastogens with N-acylethanolamines to address various health disorders [4] Group 2: Health Impact and Market Potential - Metabolic syndrome affects up to one-third of U.S. adults, increasing the risk of serious health issues such as heart disease and type 2 diabetes [3] - The proprietary combination therapy aims to leverage MEAI's pharmacological profile and PEA's anti-inflammatory properties to provide a safe and effective treatment for these health challenges [3] Group 3: Company Strategy and Intellectual Property - The company is committed to developing breakthrough therapies for complex health conditions, with a focus on metabolic syndrome and obesity [5] - Clearmind's intellectual property portfolio currently consists of 19 patent families, including 31 granted patents, with plans to seek additional patents as warranted [6]

Core Insights - SciSparc Ltd. has announced a collaboration with Clearmind Medicine Inc. that has resulted in the publication of an international patent application under the Patent Cooperation Treaty (PCT) [1] - The patent application covers a combination therapy of Clearmind's 5-methoxy-2-aminoindane (MEAI) and SciSparc's Palmitoylethanolamide (PEA) aimed at treating metabolic syndrome and obesity [2] - Metabolic syndrome affects up to one-third of U.S. adults, increasing the risk of serious health issues such as heart disease and type 2 diabetes [3] - The collaboration has led to the filing of 13 patent families across multiple jurisdictions, focusing on innovative therapies for mental health disorders and metabolic conditions [4] Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing cannabinoid-based therapies, with ongoing programs targeting Tourette Syndrome, Alzheimer's disease, autism, and status epilepticus [5] - Clearmind Medicine Inc. is a clinical-stage psychedelic pharmaceutical biotech company dedicated to developing psychedelic-derived therapeutics for health issues like alcohol use disorder, with a portfolio of 19 patent families [6]

Core Viewpoint - SciSparc Ltd. is progressing with its proposed merger with AutoMax Motors Ltd., which will enhance its portfolio in the electric vehicle sector while maintaining its focus on cannabinoid pharmaceuticals [1][2]. Group 1: Merger Details - SciSparc and AutoMax entered into a merger agreement in April 2024, where SciSparc will acquire 100% of AutoMax's share capital through a reverse merger [2]. - The merger is subject to customary closing conditions, including shareholder approvals from both companies and Israeli court approval [2]. - Special meetings for shareholder votes on the merger are scheduled for August 25, 2025, for SciSparc and August 28, 2025, for AutoMax [2]. Group 2: Regulatory Approvals - The U.S. Securities and Exchange Commission (SEC) declared effective the registration statement on Form F-4 regarding the merger on July 21, 2025 [3]. Group 3: Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders, with drug development programs targeting Tourette Syndrome, Alzheimer's disease, and autism spectrum disorder [4]. - The company also has a controlling interest in a subsidiary that sells hemp seed oil-based products on Amazon [4].

Core Insights - SciSparc Ltd. has filed a new international patent application in collaboration with Clearmind Medicine Inc. for a combination therapy targeting obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) [1][2][3] Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders and rare diseases, with a portfolio that includes cannabinoid pharmaceuticals [4] - The company is currently developing drugs such as SCI-110 for Tourette Syndrome and SCI-210 for autism and status epilepticus [4] Industry Context - Obesity affects over 890 million people globally and is a significant risk factor for chronic conditions, while non-alcoholic fatty liver disease (NAFLD) impacts more than 30% of the adult population [2] - There is a limited number of treatment options available for these health challenges, highlighting the potential market opportunity for innovative therapies [2]